We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ambrian | LSE:AMBR | London | Ordinary Share | GB0003763140 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.25 | 1.75 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMBR Ambrian Capital PLC 05 January 2010 Embargoed: 0700hrs, 5 January 2010 Ambrian Capital plc Ambrian Hires Leading Life Sciences Equities Team LONDON, 5 January 2010 - Ambrian Partners Limited ("Ambrian"), a wholly-owned subsidiary of Ambrian Capital plc, has hired a leading life sciences equities team to be led by Julian Burn-Callander, a former Head of Equity Sales and founding partner of Code (now Nomura Code) Securities. Prior to Nomura Code Securities Julian Burn-Callander, who has been in the equity markets for over thirty years, previously led Healthcare Specialist Sales at Panmure Gordon and was formerly Head of Equity Sales at SocGen. He will be joined by three highly experienced life sciences analysts, also founding partners of Code Securities: Paul Diggle, Mike Ward and Dr Chris Redhead. Paul Diggle, who has held a number of senior life sciences research positions including Head of Global Healthcare at S.G. Warburg, will initiate coverage of European large-cap pharmaceutical companies. Paul will work alongside Mike Ward, a specialist salesman and analyst who has held positions at both NatWest Markets and Deutsche Bank. Earlier in his career Mike spent a number of years at Glaxo Holdings and Sandoz (now Novartis). Dr Chris Redhead has more than ten years experience providing investment research of small and mid-cap biotechnology, diagnostics and, more latterly, biologically-based cleantech companies. He has played a pivotal role in a range of significant fund-raisings and M&A transactions in the European life sciences sector and, together with Julian Burn-Callander, will form a strong team focused on small and mid-cap corporate client opportunities. Richard Chase, Managing Director of Ambrian Partners, commented, "Ambrian Partners is seeking to build on its strong market positions in metals & mining, oil & gas and cleantech by hiring leading teams and individuals in certain key growth sectors. Julian and the team are very highly respected and are sure to make an important contribution as we seek to broaden the range of our specialist sectors. We are delighted to have recruited one of the top healthcare equities teams in the City." - Ends - For further press information please contact: Richard Chase, Managing Director Ambrian Partners Limited +44 (0)207 634 4700 Ben Simons or Charlotte Kirkham M: Communications +44 (0)207 920 2340 / 2331 About Ambrian Capital plc Ambrian Capital (AIM: AMBR) is the holding company of Ambrian Partners Limited, Ambrian Commodities Limited and Ambrian Metals Limited. Ambrian Partners Limited is a focused investment bank known in the market today for its leading positions in the metals & mining, oil & gas and cleantech sectors. It provides corporate finance advice, equity research, sales and trading and market making services. Ambrian Partners has been ranked first in the AIM Basic Materials Sector in the Hemscott Advisers Rankings and was voted No. 1 for small and mid-cap mining in the Extel Survey of fund managers in 2009. Ambrian Partners is a member of the London Stock Exchange and is authorised and regulated by the Financial Services Authority. For further information on Ambrian Capital, please visit: www.ambrian.com This information is provided by RNS The company news service from the London Stock Exchange END NRAUGURAGUPUGQC
1 Year Ambrian Capital Chart |
1 Month Ambrian Capital Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions